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Genes disrupted in schizophrenia may be revealed
by de novomutations in affected persons from other-
wise healthy families. Furthermore, during normal
brain development, genes are expressed in patterns
specific todevelopmental stageandneuroanatomical
structure.We identified de novomutations in persons
with schizophrenia and then mapped the responsible
genes onto transcriptome profiles of normal human
brain tissues from age 13 weeks gestation to adult-
hood. In the dorsolateral and ventrolateral prefrontal
cortex during fetal development, genes harboring
damagingdenovomutations in schizophrenia formed
a network significantly enriched for transcriptional
coexpression and protein interaction. The 50 genes
in the network function in neuronal migration, synap-
tic transmission, signaling, transcriptional regulation,
and transport. These results suggest that disruptions
of fetal prefrontal cortical neurogenesis are critical to
the pathophysiology of schizophrenia. These results
also support the feasibility of integrating genomic
and transcriptome analyses to map critical neurode-
velopmental processes in time and space in the brain.
INTRODUCTION
Schizophrenia is a complex brain disorder characterized by
aberrant perceptions, thought processes, and behavior. It is518 Cell 154, 518–529, August 1, 2013 ª2013 Elsevier Inc.one of the leading causes of disability worldwide (Press, 2008)
and is both highly heritable and highly genetically heterogeneous
(McClellan and King, 2010). Individually rare gene-disrupting
copy number variants (CNVs) contribute substantially to the
disorder (Walsh et al., 2008; Xu et al., 2008; Stefansson et al.,
2008; International Schizophrenia Consortium, 2008)—in partic-
ular, CNVs that disrupt genes involved with signaling, synaptic
plasticity, and neurodevelopmental processes (Walsh et al.,
2008; Kirov et al., 2012). These mutations are de novo or recent
in origin, with de novo CNVs specifically enriched in patients with
sporadic, rather than familial, illness (Xu et al., 2008; Kirov et al.,
2012). Most rare gene-disrupting CNVs detected in affected per-
sons are unique, although some recur independently at genomic
hot spots, including on chromosomes 1q21.1, 3q29, 15q11.2,
15q13.1, 16p11.2, and 22q11.2 (McClellan and King, 2010) and
at the neuropeptide receptor VIPR2 (Vacic et al., 2011).
Advances in genomics and neurobiology have enabled the
next generation of these studies. The analysis of de novo muta-
tions in schizophrenia can now include point mutations and small
insertions and deletions (indels), as well as CNVs (Girard et al.,
2011; Xu et al., 2011, 2012). In parallel, transcriptome databases
of the human brain have been generated (Kang et al., 2011;
Hawrylycz et al., 2012). Integrating these approaches has led
to new insights into genetic aberrations in mental illness. For
example, patterns of gene expression distinguishing frontal and
temporal cortex have been shown to be significantly attenuated
in brains of persons with autism (Voineagu et al., 2011). Further-
more, genes implicated in schizophrenia, including some
harboring de novo mutations, have been shown to cluster in net-
works that are highly expressed in the brain, particularly during
prenatal development (Xu et al., 2012; Gilman et al., 2012).
Table 1. De Novo Mutations in Probands with Schizophrenia and Their Unaffected Siblings
Mutation type
Probands (n = 105) Unaffected Siblings (n = 84) Total (n = 189)
Damaginga Benign All de novo Damaginga Benign All de novo All de novo
Frameshift 4 0 4 1 0 1 5
Nonsense 7 0 7 5 1 6 13
Missense 41 15 56 24 12 36 92
Silent 0 31 31 0 19 19 50
Splice 2 0 2 5 0 5 7
CNV 3 0 3 0 0 0 3
Total 57 46 103 35 32 67 170
aPredicted to be damaging based on criteria described in text.The goal of this project was to identify temporal and spatial
processes of brain development critical to the neuropathogene-
sis of schizophrenia. Our approach was to examine the con-
tribution of de novo mutations to schizophrenia and then to
characterize functional networks in the brain of the genes
harboring these mutations. The study design integrates geno-
mics, transcriptomics, and proteomics. We first identified genes
harboring de novo putatively damaging mutations in persons
with schizophrenia from otherwise healthy families. We then
evaluated the extent to which the proteins encoded by these
genes interact and the extent to which they are transcriptionally
coexpressed in different brain regions across developmental
stages. The coexpression and protein interaction profiles were
then used to generate a network whose interconnectedness
was quantifiable by the number of connections (edges) between
implicated genes. Across brain regions and developmental
stages, we compared the interconnectedness of networks of
genes harboring de novo mutations in probands versus net-
works from 10,000 simulations of genes harboring de novo
mutations in unaffected persons.
RESULTS
Identification of De Novo Mutations by Whole-Exome
Sequencing
De novo mutations were identified by exome sequencing of
quads and trios comprised of a proband with schizophrenia,
his/her unaffected parents, and, whenever available, an unaf-
fected sibling. Families were selected for negative family history
of severe mental illness other than the proband; that is, the pro-
bands were sporadic, or singleton, cases. The study design was
based on quads because unaffected siblings provide ideal con-
trols for ancestry, for nongenetic familial effects, and for sam-
pling strategy (Sebat et al., 2007). A quad-based study design
also optimizes experimental conditions because the affected
and unaffected persons are sequenced in the same way and
the same variant-assessment filters are applied to all subjects,
blind to disease status. In each family, de novo variants were
identified by comparing exome sequences of each child to his/
her parents. Variants were experimentally validated as present
in the child and absent from both parents, then classified as
damaging or not damaging to protein function as defined in the
Experimental Procedures. Exome sequencing of genomic DNAwas carried out for 399 persons, including 105 probands with
schizophrenia, 84 unaffected siblings, and their 210 unaffected
parents (Table S1 and Figure S1 available online).
We first considered all de novo point mutations in probands
and unaffected siblings, regardless of predicted effect on protein
function. Of the 105 probands, 66 probands (63%) carried 96 de
novo point mutations, 0.91mutations per individual; of the 84 un-
affected siblings, 39 siblings (46%) carried 66 such mutations,
0.79 mutations per individual (Table 1). The difference reflects
a modest enrichment among probands in the likelihood of car-
rying at least one de novo mutation (X2 = 5.10; p = 0.024).
Combining silent, missense, and nonsense mutations yields
155 de novo point mutations in coding sequence, of which
68% (105/155) were nonsynonymous, which is similar to most
previous studies of schizophrenia and autism (Xu et al., 2012;
Iossifov et al., 2012; O’Roak et al., 2012b: Neale et al., 2012;
Sanders et al., 2012) (Table S2). Mutation frequency was distrib-
uted as a Poisson distribution with mean 0.82 (Figure 1A).
The likelihood of carrying at least one de novo mutation was
related to paternal age at conception (Kong et al., 2012). Among
offspring of the youngest third of fathers, ages 19–28 years, 47%
(33/70) carried at least one de novomutation; among offspring of
the oldest third of fathers, ages 33–45 years, 76% (50/66) carried
at least one de novo mutation (X22 = 13.96, p = 0.0009; Table S1
and Figure 1B). The relationship between paternal age and
de novo mutations was the same for affected and unaffected
siblings.
We next considered de novo mutations of all classes (point
mutations, indels, and CNVs) predicted to damage protein func-
tion. Of the probands, 47/105 (45%) carried 57 de novo
damaging mutations, 0.54 damaging mutations per individual;
of the unaffected siblings, 25/84 (30%) carried 35 such muta-
tions, 0.42 per individual (Table S3). This difference reflects a
modest enrichment among probands in the likelihood of carrying
at least one de novo damaging mutation (Figure 1C; odds ratio
[OR] = 1.91, X2 = 4.45; p = 0.035). Based on this sample, the pro-
portion of schizophrenia attributable to de novo damaging muta-
tions is 21% (see Experimental Procedures).
Schizophrenia Gene Networks
We next examined how genes harboring de novo putatively
damaging mutations might reveal networks critical to develop-
ment of schizophrenia. The analysis addressed three questions.Cell 154, 518–529, August 1, 2013 ª2013 Elsevier Inc. 519
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Figure 1. De Novo Mutations in Persons with Schizophrenia and Unaffected Siblings
(A) All de novo point mutations in 189 persons (Table S3). Observed numbers of events fit a Poisson distribution with m = 0.87 events per person. R2 = 0.97 for
goodness of fit of observed to expected values under Poisson assumption.
(B) De novo point mutations in 189 offspring by terciles of paternal age. Presence of at least one de novo point mutation is associated with older paternal age
(X22 = 13.96, p = 0.0009).
(C) Presence of at least one de novo putatively damaging mutation in schizophrenia probands and unaffected siblings. 45% (47/105) of the probands and 30%
(25/84) of the unaffected siblings carried at least one damaging de novo mutation (X2 = 4.45, p = 0.035).
(D) Genes harboring de novo damagingmutations in personswith schizophrenia. Colors represent types ofmutations: blue aremissense, red are nonsense, black
are frameshift, green are splice, and orange are CNVs.First, do genes with de novo damaging mutations in schizo-
phrenia form larger and/or more interconnected protein interac-
tion networks than do genes with de novo damaging mutations
in controls? Second, is there evidence for transcriptional
coexpression of genes harboring these mutations in any brain
regions across different stages of development? Third, com-
bining protein interaction and transcriptome data, what networks
are generated by the genes harboring de novo damaging muta-
tions in schizophrenia, and which genes are included in these
networks?
Overall, 54 different genes harbored de novo damaging point
mutations, indels, or single-gene-disrupting CNVs in probands
(Table S3A). Each of these genes was included in protein interac-
tion and coexpression analyses. For de novo CNVs, genes were
included if disrupted by breakpoints, but not if completely
deleted or duplicated.
For comparison, we considered genes carrying de novo
damaging mutations in healthy siblings from this study (Table520 Cell 154, 518–529, August 1, 2013 ª2013 Elsevier Inc.S3B) and from four previous exome studies of schizophrenia
and autism (Xu et al., 2012; Iossifov et al., 2012; O’Roak et al.,
2012b; Sanders et al., 2012). From the five studies combined,
264 genes in unaffected siblings harbored de novo mutations
predicted to be damaging based on the same criteria used to
define de novo damaging events in our probands (Experimental
Procedures and Table S4). We carried out the same analyses on
10,000 sets of 54 control genes, each randomly selected from
the pool of 264 genes. We constructed a network for each set
of 54 genes, yielding 10,001 networks, including the network
based on case genes, and counted the numbers of nodes and
edges for each.
Protein-Protein Interaction Networks of Genes with
De Novo Mutations
We used the GeneMania physical interaction data set (Mostafavi
et al., 2008) to examine whether genes disrupted by de
novo damaging events in probands clustered in protein-protein
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Figure 2. Interconnectedness of PPI Networks Based on Genes
Harboring De Novo Mutations
(A and B) The 54 genes harboring de novo damaging mutations in schizo-
phrenia cases yield a PPI network of 18 genes (A) and 23 interactions (B),
indicated by the vertical dotted lines. For comparison, 10,000 sets of 54 genes
were selected at random from 264 genes harboring de novo damaging
mutations in unaffected siblings (controls). Each of these 10,000 gene sets also
yields a PPI network. The numbers of genes and connecting links for each of
these 10,000 control networks were plotted in (A) and (B), respectively.
p values for enrichment of genes and connections in the case network were
estimated by the proportion of control networks with more genes or in-
teractions than the case network. The network based on cases is enriched
both for number of genes (p = 0.002) and for number of connections between
genes (p = 0.0005).
(C and D) Analogous networks based on genes harboring de novo benign
events in cases and in controls. The networks based on genes with de novo
benign events in cases do not differ from networks based on genes with de
novo benign mutations in controls.interaction (PPI) networks. Of the 54 proband geneswith de novo
damaging mutations, 18 genes mapped to an interconnected
PPI network with 23 edges. We evaluated this network by
comparing its numbers of nodes and edges to the distribution
of nodes and edges of 10,000 simulated networks of genes car-
rying de novo damaging events in healthy siblings (Figures 2A
and 2B). The network of genes harboring de novo damaging
mutations in schizophrenia had significantly more nodes (p =
0.002) and edges (p = 0.0005) than networks of genes harboring
de novo damaging mutations in siblings. In contrast, the network
of genes harboring de novo benign events in the probands had
no more nodes or edges than networks of genes harboring de
novo benign events in siblings (Figures 2C and 2D).
Transcriptional Coexpression Networks of Genes with
De Novo Mutations
Next, we evaluated transcriptional coexpression across different
brain regions at different developmental periods for genes
harboring de novo mutations in probands with schizophreniaand for genes harboring de novo mutations in unaffected sib-
lings. Using publicly available RNA sequencing (RNA-seq)-
based gene expression levels from the BrainSpan: Atlas of the
Developing Human Brain (http://www.brainspan.org), we gener-
ated networks reflecting profiles of coexpressed genes.
Tissues from the BrainSpan Atlas were divided into four
anatomic regions—frontal cortex (FC), temporal and parietal re-
gions (TP), sensory-motor regions (SM), and subcortical regions
(SC)—and three developmental stages—fetal (13–26 postcon-
ception weeks), early infancy to late childhood (4 months to 11
years), and adolescence to adulthood (13–23 years) (Table S5).
The number of tissues included by the BrainSpan Atlas ranged
from 5 to 6 for children and young adults to 11 to 12 for fetal tis-
sues. For each pair of proband genes and each pair of control
genes, we calculated Pearson correlation coefficients for RNA-
seq expression levels across tissues within each brain region
and each developmental stage. For each set of tissues, we
therefore calculated correlation coefficients for (54 3 53)/2 =
2,860 gene pairs. Gene pairs with jRj R 0.8 were defined as
‘‘connected’’ in subsequent network constructions. Network
interconnectedness was measured by the number of connec-
tions, or edges (Baraba´si and Oltvai, 2004).
Numbers of edges in the networks of schizophrenia genes and
control genes for each brain region by developmental stage are
shown in Figure 3. The most striking result is that, in fetal frontal
cortex, coexpression of genes harboring de novo damaging
mutations in probands yields a network with significantly greater
connectedness than networks derived from genes harboring de
novo damaging mutations in controls (nominal p = 0.00006;
corrected for multiple comparisons, p = 0.0007) (Figure 3 and
Table S6). Connectedness was not significantly greater for
case genes than for control genes at other developmental
periods. There was no significant enrichment for connectedness
in networks based on case genes harboring de novo benign
mutations (Figure S2).
Given the significant interconnectedness of coexpressed case
genes in fetal frontal cortex, we carried out the same analyses for
four anatomical subregions of fetal frontal cortex: dorsolateral
prefrontal cortex, ventrolateral prefrontal contex, medial prefron-
tal cortex, and orbital frontal cortex. Coexpression profiles of
genes mutant in schizophrenia differed most significantly from
those of unaffected siblings in tissues from fetal dorsolateral pre-
frontal cortex (nominal p = 0.0001; corrected p = 0.0005) and
fetal ventrolateral prefrontal cortex (nominal p = 0.0004; cor-
rected p = 0.002) (Figure 4 and Table S7).
A Merged Network of Protein Interaction and
Transcriptional Coexpression in the Dorsolateral and
Ventrolateral Prefrontal Cortex during Fetal
Development
We then merged the coexpression network derived for schizo-
phrenia genes in fetal dorsolateral and ventrolateral prefrontal
cortex with the PPI network derived for the same genes. The
merged network encompasses 50 of the 54 genes harboring
damaging de novo mutations in subjects with schizophrenia,
with 126 connections among these genes (Figure 5). Genes in
the network function in biological processes critical to neuro-
genesis and synaptic integrity, including axon guidance andCell 154, 518–529, August 1, 2013 ª2013 Elsevier Inc. 521
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Figure 3. Interconnectedness of Transcriptional Coexpression Networks at Various Developmental Stages and in Different Brain Regions
Based on Genes Harboring De Novo Damaging Mutations
Coexpression of genes harboring de novo damagingmutations in cases and in controls was evaluated using RNA-seq data from the BrainSpan Atlas. Gene pairs
were defined as coexpressed if jRj R 0.8 for their RNA-seq expression levels across all tissues from a given brain region and a given developmental stage.
Networks were created for coexpressed gene pairs as described for Figure 2B. Dotted lines indicate numbers of connections (edges) in networks created using
genes with de novo damaging mutations in cases. Histograms represent distributions of the numbers of edges in 10,000 simulated networks using genes with
de novo damaging mutations in controls. The most significant enrichment for coexpression of genes mutant in schizophrenia was observed in frontal cortex
during fetal development (p = 0.00006; Table S6). There was no enrichment for coexpression of genes with de novo benignmutations in schizophrenia compared
to controls (Figure S2).neuronal migration, signaling, cell proliferation, transport, synap-
tic transmission, and transcriptional regulation. Expression
levels in fetal frontal cortex of individual network genes are
provided in Figure 6. Expression levels of most of the genes
are high early in fetal development, decline at the end of fetal
development and in childhood, and gradually increase again in
early adulthood. Expression of other genes either increases
throughout fetal and adult development or remains at stable
levels over time (Figure 6).
DISCUSSION
The Prefrontal Cortex and Its Role in Schizophrenia
Damaging de novo mutations in persons with schizophrenia
converge in a network of genes coexpressed in the dorsolateral
and ventrolateral prefrontal cortex during fetal development.522 Cell 154, 518–529, August 1, 2013 ª2013 Elsevier Inc.These results support the neurodevelopmental hypothesis, pro-
posed 25 years ago, that disruptions in fetal prefrontal cortical
development are core mechanisms underlying schizophrenia
(Weinberger, 1987; Marı´n, 2012). The specific timing and
anatomic locale of the gene network and the biological functions
of its component genes suggest that mutations leading to
schizophrenia disrupt the orchestration of cortical neurogenesis.
Human brain evolution is distinguished by the remarkable
expansion of the surface area and cytoarchitectural complexity
of the neocortex, particularly in the prefrontal cortex. Healthy
adult cortical function emerges from synchronized spatiotem-
poral neuronal migration during fetal development, which
depends upon the complex regulation of cellular proliferation,
signaling, and transcription pathways (Rakic, 2009). Many genes
orchestrate these processes, the disruption of any one of which
may result in loss of cortical integrity and neuronal homeostasis,
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Figure 4. Interconnectedness of Transcrip-
tional Coexpression Networks from Four Sub-
regions of the Fetal Frontal Cortex
Tissues from the fetal frontal cortex with RNA-seq data
in the BrainSpan Atlas were classified by subregion.
Networks were then created, as described for Fig-
ure 3, for genes with de novo damaging mutations in
cases and in controls (left) and for de novo benign
mutations in cases and in controls (right). The greatest
enrichments for coexpression of genes with de novo
damaging events were observed in the dorsolateral
and ventrolateral prefrontal cortex (Table S7). There
were no regions enriched for coexpression of genes
harboring de novo benign mutations in cases.leading to neuropsychiatric disease (Ramocki and Zoghbi,
2008).
Prefrontal cortical networks organize input from other cortical
and subcortical brain regions to plan and direct motor, cognitive,
affective, and social behaviors (Kolb et al., 2012). The dorsolat-
eral and ventrolateral prefrontal cortices are distinct neuroana-
tomic structures, with complementary neurocognitive functions.
The dorsolateral prefrontal cortex is linked to cognitive control,
which requires the coordination of attention and working mem-
ory to address changing environments and task demands. The
ventrolateral prefrontal cortex is associated with reward learning
and decision making, which depend upon the ability to gauge
potential outcomes in the context of incoming stimuli as a guide
to making choices (Gla¨scher et al., 2012). These executive func-
tions endow humans with enormous capacity for problem solv-
ing and adaptation to a wide range of environments.Cell 154, 518Several lines of evidence support the
role of the prefrontal cortex in schizo-
phrenia. Deficits in executive functions are
characteristic of the illness and often pre-
date its onset (Kalkstein et al., 2010). The
prefrontal cortex matures late in brain
development, with gray matter consoloda-
tion and myelination extending into early
adulthood—the timing of which is consis-
tent with ages of onset of schizophrenia
(Gogtay et al., 2004). Neuroimaging studies
of schizophrenia have demonstrated
anatomical and functional deficits in the
region (Shepherd et al., 2012). Postmortem
brain studies have found a variety of
cellular pathological findings in prefrontal
cortical tissue (Eisenberg and Berman,
2010). Further, a substantial portion of
prefrontal cortical neurons express mono-
aminergic receptors that are targets of
antipsychotic medications (Masana et al.,
2012). Our results suggest that deficits in
prefrontal cortex executive functions are
manifestations of schizophrenia, with full
presentation occurring as key brain regions
mature. Integrating genomic data with
transcriptome network analyses can helppinpoint anatomical and developmental mechanisms that are
disrupted in this process.
A key feature of schizophrenia appears to be brain disconnec-
tivity—i.e., aberrant connections with and between different
brain regions (Fitzsimmons et al., 2013). The prefrontal cortex
is normally highly interconnected with other cortical, basal
ganglia, and limbic regions. Human brain development depends
upon the coordinated temporal and spatial regulation of neuronal
migration in order to establish integrated cortical networks (Uhl-
haas and Singer, 2012). Disruptions of individual components
within developing neuronal networks may impact the functional
integrity of larger dynamic brain systems (Vidal et al., 2011).
Therefore, our results do not preclude the involvement of other
brain regions in schizophrenia nor imply that damaging muta-
tions have an impact only during fetal development. Genes
harboring de novo damaging mutations in schizophrenia are–529, August 1, 2013 ª2013 Elsevier Inc. 523
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Figure 5. Network of Genes Harboring Damaging De Novo Mutations in Schizophrenia that Are Coexpressed in Fetal Dorsolateral and
Ventrolateral Prefrontal Cortex
Merging data from networks of PPI network and of coexpression in fetal dorsolateral (DFC) and fetal ventrolateral (VFC) yields a network of 50 genes (nodes) with
126 connections (edges). Red lines represent coexpressed genes, and blue lines represent physical connections between protein products of the genes.expressed inmultiple brain regions (and other tissues) across the
lifespan. Neuroimaging studies of schizophrenia describe multi-
ple anatomical abnormalities, including decreased total brain
volumes and losses of gray matter in the anterior cingulate, fron-
tal and temporal lobes, hippocampus, amygdala, thalamus, and
insula (Shepherd et al., 2012).
Roles in Brain Development of Genes with De Novo
Mutations in Schizophrenia
Genes implicated in schizophrenia and autism function in pro-
cesses important to fetal brain development, including axon
guidance, neuronal cell mobility, synaptic function, and chromo-
somal remodeling (Gilman et al., 2012; Xu et al., 2012). Most of
the genes with damaging de novo mutations in probands are
known to play critical roles in developing brain, including
neuronal migration (ITGA3, LAMA2; Anton et al., 1999; Relucio
et al., 2009), axon guidance (SLIT2, SLIT3; Zhang et al., 2012),
signal transduction and cell adhesion (CELSR2; Shima et al.,
2007), cellular proliferation (MKI67; Duchrow et al., 1995), tran-
scriptional regulation of glial and neuronal development (DTX1,
HIF1A, NCOR2; Patten et al., 2006; Pacary et al., 2007; Jepsen
et al., 2007), and neurotransmitter signaling and synaptic trans-
mission (ADCY9, CACNA1I, GLS, SLC18A2; Martin et al., 2007;
Simons et al., 2013).
Several network genes with de novo mutations in probands
function in neurotransmitter pathways. ADCY9 is involved in
neuronal signaling in glutamate and GABA pathways (Martin
et al., 2007). SLC18A2 encodes the vesicular monoamine trans-
porter VMAT2, which is responsible for pumping serotonin,
dopamine, norepinephrine, epinephrine, and histamine into ves-524 Cell 154, 518–529, August 1, 2013 ª2013 Elsevier Inc.icles for use in synaptic transmission (Simons et al., 2013). GLS
catalyzes the hydrolysis of glutamine to glutamate. Studies of
GLS knockout mice suggest that dysregulation of glutaminase
function could play a role in schizophrenia and that medications
inhibiting glutaminase may have a therapeutic benefit for the
illness (Gaisler-Salomon et al., 2012).
CACNA1I, the only gene disrupted by damaging de novo
mutations in more than one patient, is a brain-specific, T type
calcium channel involved in regulation of differential patterns of
neuronal firing in the thalamus, striatum, nucleus accumbens,
and prefrontal cortex (Chemin et al., 2002; Talley et al., 1999;
Yunker et al., 2003). In rats, T type calcium channel antagonists
reduced amphetamine-induced psychomotor activity and gluta-
mate release, patterns predictive of antipsychotic effects
(Uslaner et al., 2012). The therapeutic activity of antipsychotic
medications, including clozapine, may stem in part from the inhi-
bition of T type calcium channels (Choi and Rhim, 2010).
Our results provide further evidence for the genetic complexity
and heterogeneity of schizophrenia. Several network genes have
been implicated previously in schizophrenia and other neuropsy-
chiatric disorders, including LAMA2 (Xu et al., 2012), DNTM1
(Costa et al., 2007), and SLC25A1 and CLTCL1, both of which
are located in the chromosome 22q11.2 deletion region that
confers substantial risk for schizophrenia. Expression profiles
of CELSR2, HIVEP1, ITGA3, SERPINI1, and SLIT2 differed
between neurons induced from stem cells of persons with
schizophrenia versus controls (Brennand et al., 2011). Nine
patients carried de novo damaging mutations in more than one
gene (Table S8), suggesting the possibility of oligogenic influ-
ences on disease (Girirajan et al., 2012).
Causality
Given the degree of genetic heterogeneity of mental illness,
establishing causal links between individual genes and schizo-
phrenia will depend on both biological and statistical evidence.
The sample size of this study both limits the power of network
analyses and is not sufficient to prove causality of any one
gene. Resequencing studies of candidate genes in very large
cohorts may provide such statistical evidence, as has been
demonstrated for autism (O’Roak et al., 2012a).
The goal of modern genetic studies of mental illness is to iden-
tify key pathways that, when disrupted, lead to disease, realizing
that mutation of any of multiple genes may disrupt the same
pathway (McClellan and King, 2010). Our goal for this project
has been to use computational tools to define gene networks
based on mutations in affected individuals, thereby providing
empiric evidence that the networks are related to schizophrenia.
The next step is to discover the biological pathways that underlie
the computational networks (Konopka et al., 2012).The principal
limitation in doing so is incomplete understanding of normal
brain development. As pathways critical to neurodevelopment
are revealed by mutations that disrupt them, it will become
possible to carry out statistical testing for mutations leading to
loss of integrity of a pathway rather than of a single gene.
Our results suggest that disruption of genes critical to neuro-
genesis of the prefrontal cortex are also critical to pathogenesis
of schizophrenia. These findings have implications for the devel-
opment of more biologically specific treatments of the illness
(Insel, 2009). Given ethical, clinical, and neurobiological limita-
tions to in utero interventions, treatment research inevitably
focuses on compensatory strategies that address downstream
effects on brain development. Medications targeting glutamate
and T type calcium channel pathways are potential therapeutic
mechanisms suggested by mutant genes in our patients.
Large-scale collaborative efforts in genomics and neurobiology
are needed to reveal additional therapeutic targets based on
the genes and biological mechanisms underlying brain circuitry
(Akil et al., 2010).
EXPERIMENTAL PROCEDURES
Exome Sequencing
From genomic DNA of the 399 participants, library construction, exome cap-
ture, and sequencing were carried out as previously described (Walsh et al.,
2010) with some modifications. Genomic DNA libraries were captured by
SeqCap EZ Exome v2 (Nimblegen) pools and then hybridized to bio-
tynylated capture probes and sequenced to median depth of coverage of
at least 1003. Paired-end sequence reads (2 3 101 bp) were collected,
demultiplexed, filtered for quality, aligned to exome targets using BWA
v0.6.1-r104, realigned with GATK v1.5-21, and then genotypes were called
with MAQ v0.7.1, SAM tools v0.1.18, and GATK v1.5-21. For individual sam-
ples, on average, 93% of targeted coding regions were covered at R 103
and 84% at R 203. For joint coverage of trios (Iossifov et al., 2012), on
average, 89% of targeted coding regions were covered at R 103 and
77% at R 203 (Figure S1).
Artifacts were excluded by comparison with 800 exomes previously
sequenced on the same instrument in our lab. Common variants, with
MAF > 0.001 in dbSNP v137 or in the NHLBI Exome Sequencing Project
(2012), were also excluded. To detect point mutations and small insertions
and deletions (1–23 bp in length), variants were retained at sites with at least
30%of total reads representing the variant after adjusting by individual inspec-
tion for genomic complexities (e.g., multiple pseudogenes of CHEK2). Noconstraint was put on the proportion of variant reads in parental samples.
Candidate de novo variants were tested by diagnostic PCR and Sanger
sequencing. To detect CNVs, exome-based calls were made by CoNIFER
(Krumm et al., 2012) and then validated by TaqMan in DNA from the proband
or sibling and from the parents. For de novo CNVs not flanked by segmental
duplications, exact genomic breakpoints were determined with diagnostic
PCR primers and Sanger sequencing. De novo variants included in subse-
quent analyses were defined as variants of any type demonstrated by both
exome sequencing and Sanger sequence validation to be present in a proband
or a sibling and absent from both parents.
The predicted functional impact of each candidate de novomissense variant
was assessed with in silico tools. Variants that met any of the following criteria
were considered potentially damaging: frameshift; nonsense (unless the intro-
duced nonsense was polymorphic or the natural stop in other species);
missense mutation with Polyphen score R 0.90 and/or SIFT p < 0.05 and/or
Grantham score > 100 (Adzhubei et al., 2010; Kumar et al., 2009; Grantham,
1974); CNV disrupting a gene or completely deleting a gene or genes; or splice
or enhancer alteration predicted by one or more algorithms and with GERP
score > 5.0.
Proportions of probands and unaffected siblings with point mutations and
with damaging mutations of all classes, were compared by chi-square tests
using standard procedures. Attributable risk was estimated by p(OR – 1)/
[p(OR - 1) + 1] (Schlesselman, 1982), where p is the proportion of controls (un-
affected siblings) with a de novo damaging mutations and OR is the odds ratio
for harboring a de novo damaging mutation in cases versus controls.
Network Construction
Physical interactions from the Homo sapiens database were collected from
GeneMANIA 2011-08-03 release of 150 studies (Mostafavi et al., 2008).
There were 753,875 physical interactions in 12,010 proteins after removing
duplicates. A physical interaction network was created for the schizophrenia
genes and for each simulation gene set. Degree is defined as the number of
neighbors of each node (Baraba´si and Oltvai, 2004; Watts and Strogatz,
1998).
Coexpression-based network analyses were conducted using existing data
sets in the BrainSpan: Atlas of the Developing Human Brain. Normalized gene
expression levels for 26 different brain tissues in 10 different developmental
periods were obtained from the BrainSpan RNA-seq data set v3 of developing
human brain. Tissue qualification, processing and dissection, and experi-
mental and bioinformatics procedures are described in the technical white
paper of the data set (http://help.brain-map.org/display/devhumanbrain/
Documentation) (Supplemental Information). Network figures were created
using Cytoscape 2.8.3 (Smoot et al., 2011).
To estimate the statistical significance of networks created from PPI and
coexpression data, we generated a data set of de novo predicted damaging
mutations among unaffected siblings by pooling results from unaffected
siblings in this study with results from unaffected siblings reported in autism
and schizophrenia exome studies (Xu et al., 2012; Iossifov et al., 2012;
O’Roak et al., 2012b; Sanders et al., 2012). We excluded variants observed
in both probands and unaffected siblings, variants without a defined nucleo-
tide change, and variants reported by the authors to have failed validation.
From all unaffected siblings, 547 de novo events were included, for which
functional consequences were predicted using the same criteria applied
to probands in this study (Supplemental Information). A total of 276 events
(2 frameshift, 21 nonsense, 248missense, and 5 splice) in 267 genes were pre-
dicted to be damaging. Three genes not represented in either the GeneMania
database or the BrainSpan Atlas were removed from analysis. Using the re-
maining 264 genes with damaging de novo events in the pooled group of un-
affected siblings, we created 10,000 random gene sets that each contained 54
different genes, corresponding to the number of genes harboring predicted
damaging events in probands.
PPI and coexpression networks were constructed for each gene set. The
mean numbers and SD of nodes and edges in the simulated networks were
used to generate normal distributions for PPI networks in each of the four
anatomic regions and three developmental stages. Significance levels of net-
works based on genesmutant in probands were calculated using Z scores and
corrected as appropriate for numbers of tests.Cell 154, 518–529, August 1, 2013 ª2013 Elsevier Inc. 525
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